Soluble guanylate cyclase: A potential therapeutic target for heart failure

Mihai Gheorghiade, Catherine N. Marti, Hani N. Sabbah, Lothar Roessig, Stephen J. Greene, Michael Böhm, John C. Burnett, Umberto Campia, John G.F. Cleland, Sean P. Collins, Gregg C. Fonarow, Phillip D. Levy, Marco Metra, Bertram Pitt, Piotr Ponikowski, Naoki Sato, Adriaan A. Voors, Johannes Peter Stasch, Javed Butler

Research output: Contribution to journalArticle

55 Scopus citations

Abstract

The number of annual hospitalizations for heart failure (HF) and the mortality rates among patients hospitalized for HF remains unacceptably high. The search continues for safe and effective agents that improve outcomes when added to standard therapy. The nitric oxide (NO) - soluble guanylate cyclase (sGC) - cyclic guanosine monophosphate (cGMP) pathway serves an important physiologic role in both vascular and non-vascular tissues, including regulation of myocardial and renal function, and is disrupted in the setting of HF, leading to decreased protection against myocardial injury, ventricular remodeling, and the cardio-renal syndrome. The impaired NO-sGC-cGMP pathway signaling in HF is secondary to reduced NO bioavailability and an alteration in the redox state of sGC, making it unresponsive to NO. Accordingly, increasing directly the activity of sGC is an attractive pharmacologic strategy. With the development of two novel classes of drugs, sGC stimulators and sGC activators, the hypothesis that restoration of NO-sGC-cGMP signaling is beneficial in HF patients can now be tested. Characterization of these agents in pre-clinical and clinical studies has begun with investigations suggesting both hemodynamic effects and organ-protective properties independent of hemodynamic changes. The latter could prove valuable in long-term low-dose therapy in HF patients. This review will explain the role of the NO-sGC-cGMP pathway in HF pathophysiology and outcomes, data obtained with sGC stimulators and sGC activators in pre-clinical and clinical studies, and a plan for the further clinical development to study these agents as HF therapy.

Original languageEnglish (US)
Pages (from-to)123-134
Number of pages12
JournalHeart Failure Reviews
Volume18
Issue number2
DOIs
StatePublished - Mar 1 2013

Keywords

  • Cyclic guanosine monophosphate
  • Heart failure
  • Pathophysiology
  • Soluble guanylate cyclase
  • Treatment

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Soluble guanylate cyclase: A potential therapeutic target for heart failure'. Together they form a unique fingerprint.

  • Cite this

    Gheorghiade, M., Marti, C. N., Sabbah, H. N., Roessig, L., Greene, S. J., Böhm, M., Burnett, J. C., Campia, U., Cleland, J. G. F., Collins, S. P., Fonarow, G. C., Levy, P. D., Metra, M., Pitt, B., Ponikowski, P., Sato, N., Voors, A. A., Stasch, J. P., & Butler, J. (2013). Soluble guanylate cyclase: A potential therapeutic target for heart failure. Heart Failure Reviews, 18(2), 123-134. https://doi.org/10.1007/s10741-012-9323-1